Burning Rock Biotech (BNR) Receivables (2021 - 2023)

Burning Rock Biotech has reported Receivables over the past 3 years, most recently at $20.8 million for Q4 2023.

  • Quarterly results put Receivables at $20.8 million for Q4 2023, down 2.59% from a year ago — trailing twelve months through Dec 2023 was $20.8 million (down 2.59% YoY), and the annual figure for FY2023 was $21.1 million, down 6.74%.
  • Receivables for Q4 2023 was $20.8 million at Burning Rock Biotech, down from $21.3 million in the prior quarter.
  • Over the last five years, Receivables for BNR hit a ceiling of $21.3 million in Q4 2022 and a floor of $20.8 million in Q4 2023.
  • Median Receivables over the past 3 years was $21.1 million (2021), compared with a mean of $21.1 million.
  • Biggest five-year swings in Receivables: rose 1.33% in 2022 and later fell 2.59% in 2023.
  • Burning Rock Biotech's Receivables stood at $21.1 million in 2021, then grew by 1.33% to $21.3 million in 2022, then dropped by 2.59% to $20.8 million in 2023.
  • The last three reported values for Receivables were $20.8 million (Q4 2023), $21.3 million (Q4 2022), and $21.1 million (Q4 2021) per Business Quant data.